[Personalized medicine and molecular targets of drugs].
Progress in genomics has increased the understanding of molecular basis underlying many diseases, which has led to development of molecular targeted drugs and personalized medicine. The incorporation of several targeted drugs and the response biomarker into practice has remarkably improved patient outcomes in several diseases, and FDA has validated possible biomarkers and is using corresponding FDA-approved drug labels with 3 recommendation levels of testing, "required", "recommended", and "information only". The day of practical pharmacogenomics for the bedside has probably arrived. Even so, the results of drug development and its individualization have been rather disappointing on the whole. The contribution of genomic marker research and molecular targeted therapies to practical medicine and the problems of the day were reviewed.
Nishiyama
Masahiko
M
Research Institute for Development Therapeutics, Saitama Medical University.
D015415:Biomarkers; D006801:Humans; D058990:Molecular Targeted Therapy; D057285:Precision Medicine
D015415:Biomarkers